The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose
Open Access
- 1 January 2008
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 31 (1), 108-113
- https://doi.org/10.2337/dc07-1441
Abstract
OBJECTIVE—To evaluate the effect of treatment with the dipeptidyl peptidase (DPP)-4 inhibitor vildagliptin on insulin sensitivity and β-cell function in subjects with impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS—A total of 22 subjects with IFG (11 female and 11 male, mean ± SD age 59.6 ± 11.5 years) were treated orally with 100 mg vildagliptin once daily in a single-blind study. Subjects received placebo for 2 weeks (run-in) followed by vildagliptin for 6 weeks (treatment) and then placebo for 2 weeks (washout). A frequently sampled intravenous glucose tolerance test (FSIGT), followed by a 2-h meal tolerance test (MTT), was performed at 2, 8, and 10 weeks. From the FSIGT, the acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) were determined and used to compute the disposition index (AIRg × SI) as a measure of β-cell function. RESULTS—Fasting plasma glucose did not change after 6 weeks of vildagliptin treatment. With treatment, mean ± SEM AIRg increased from 224 ± 44 to 286 ± 52 pmol/l (P < 0.05), and SI improved from 2.8 ± 0.5 to 3.5 ± 0.5 × 10−5 · min−1 · pmol−1 · l (P < 0.01), resulting in an increase in the disposition index from 688 ± 180 to 1,164 ± 318 × 10−5/min (P < 0.05). These effects were not sustained after washout. During the MTT, the incremental area under the glucose curve was significantly decreased after treatment (240 ± 15 vs. 191 ± 14 mmol · l−1 · min−1; P = 0.002), but this effect was not sustained after washout. CONCLUSIONS—The DPP-4 inhibitor vildagliptin improves insulin sensitivity and β-cell function, leading to improved postprandial glycemia in subjects with IFG, who are known to have β-cell dysfunction. Thus, vildagliptin may prevent progression to diabetes in high-risk subjects.Keywords
This publication has 21 references indexed in Scilit:
- Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 DiabetesDiabetes, 2006
- Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose responseDiabetes, Obesity and Metabolism, 2005
- Glucagon-like peptide 1 and its derivatives in the treatment of diabetesRegulatory Peptides, 2005
- Predictors of and Longitudinal Changes in Insulin Sensitivity and Secretion Preceding Onset of Type 2 DiabetesDiabetes, 2005
- Loss of beta cell function as fasting glucose increases in the non-diabetic rangeDiabetologia, 2004
- Disturbances in β-Cell Function in Impaired Fasting GlycemiaDiabetes, 2002
- Relation of Impaired Fasting and Postload Glucose With Incident Type 2 Diabetes in a Dutch PopulationJAMA, 2001
- Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.JCI Insight, 1994
- Quantification of the Relationship Between Insulin Sensitivity and β-Cell Function in Human Subjects: Evidence for a Hyperbolic FunctionDiabetes, 1993
- Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic functionDiabetes, 1993